01796nas a2200241   4500000000100000008004100001260004400042653002400086653005700110100002100167700001600188700002100204700001700225700001800242700001500260700001400275700001800289245012200307856008500429490000700514520101900521022001401540       2022                            d  bSpringer Science and Business Media LLC10aInfectious Diseases10aPublic Health, Environmental and Occupational Health1 aKaluarachchi TDJ1 aCampbell PM1 aWickremasinghe R1 aRanasinghe S1 aYasewardene S1 aDe Silva H1 aMcBain AJ1 aWeerasekera M00aPossible clinical implications and future directions of managing bacterial biofilms in cutaneous leishmaniasis wounds  uhttps://tropmedhealth.biomedcentral.com/track/pdf/10.1186/s41182-022-00455-y.pdf0 v503 a<p>Cutaneous leishmaniasis (CL) lesions are chronic and result in disfiguring scars. The microbiological aspects of these wounds have not been systematically investigated. We have recently reported that 61.5% of CL wounds in a Sri Lankan cohort harboured bacterial biofilms, mainly composed of bacilli, Enterobacteriaceae, and Pseudomonas, which could delay wound healing. We have additionally reported that biofilms were significantly associated patients over 40&nbsp;years of age, discharge, pain and/or itching of the wound, and high pus cell counts. Using this as background knowledge and other relevant literature, we highlight the importance of investigating the role of biofilms in CL wound healing, clinical indicators, cost-effective laboratory tests involving less invasive sampling techniques for diagnosing biofilms and potential therapeutic options for biofilm-containing CL wounds, such as adjunctive application of wound debridement and antimicrobial treatment along with anti-parasitic drugs.</p>
  a1349-4147